1 – 26 of 26
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) – Unmet needs remain
(
- Contribution to journal › Article
-
Mark
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
(
- Contribution to journal › Article
- 2019
-
Mark
Hypertension and cardiovascular diseases in Swedish persons with haemophilia — A longitudinal registry study
(
- Contribution to journal › Article
- 2017
-
Mark
Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients : Results of the INSIGHT case-control study
(
- Contribution to journal › Article
- 2014
-
Mark
The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A
(
- Contribution to journal › Article
- 2012
-
Mark
Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?
(
- Contribution to journal › Letter
- 2011
-
Mark
Immune tolerance induction in patients with hemophilia A
(
- Contribution to journal › Article
-
Mark
Ovanliga ärftliga former av blödarsjuka. Blödningssymtom, familjehistoria och laboratorieanalyser ger diagnosen.
(
- Contribution to journal › Article
- 2010
-
Mark
Clinical issues in inhibitors
(
- Contribution to journal › Scientific review
-
Mark
Von Willebrands sjukdom--från biokemi till klinisk praxis.
(
- Contribution to journal › Scientific review
- 2009
-
Mark
Arandomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
(
- Contribution to journal › Article
-
Mark
Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
(
- Contribution to journal › Article
- 2008
-
Mark
Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
(
- Contribution to journal › Article
- 2007
-
Mark
Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
The APC-PCI complex concentration predicts outcome of aortic surgery.
(
- Contribution to journal › Article
- 2005
-
Mark
Protein C levels can be forecasted by global haemostatic tests in critically ill patients and predict long-term survival.
(
- Contribution to journal › Article
- 2003
-
Mark
Monitoring the bioavailability of FEIBA with a thrombin generation assay
(
- Contribution to journal › Article
-
Mark
Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay
(
- Contribution to journal › Article
-
Mark
Thrombosis in inherited factor VII deficiency.
(
- Contribution to journal › Article
- 2001
-
Mark
Anti- and procoagulant activities in factor VII-deficient subjects
(
- Contribution to journal › Article
-
Mark
Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis
(
- Contribution to journal › Article
- 2000
-
Mark
Correlation between different intensities of anti-vitamin K treatment and coagulation parameters
(
- Contribution to journal › Article
- 1998
-
Mark
Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral anticoagulation
(
- Contribution to journal › Article
-
Mark
Blödarsjuka med HIV. Långsammare infektionsförlopp hos yngre och vid större förbrukning av faktorkoncentrat
(
- Contribution to journal › Article
- 1996
-
Mark
Antitrombin III-koncentrat söker sin roll i terapin. Var försiktig och invänta studieresultat!
(
- Contribution to journal › Article